(Q39218247)

10 September 2017

Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma (English)

1 reference

10 September 2017

1 reference

Xueying Sun

12

0 references

Jagat R Kanwar

9

object named as

Jagat R Kanwar

1 reference

10 September 2017

Peng Xiu

1

1 reference

10 September 2017

Xuesong Dong

2

1 reference

10 September 2017

Xiaofeng Dong

3

1 reference

10 September 2017

Zongzhen Xu

4

1 reference

10 September 2017

Huaqiang Zhu

5

1 reference

10 September 2017

Feng Liu

6

1 reference

10 September 2017

Zheng Wei

7

1 reference

10 September 2017

Bo Zhai

8

1 reference

10 September 2017

Hongchi Jiang

10

1 reference

10 September 2017

Jie Li

11

1 reference

10 September 2017

30 January 2013

1 reference

10 September 2017

8

1 reference

inferred from page(s)

published in

Cancer Science

1 reference

10 September 2017

104

1 reference

10 September 2017

3

1 reference

10 September 2017

375-382

1 reference

10 September 2017

Global cancer statistics

1 reference

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer

21 January 2018

1 reference

Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth

21 January 2018

1 reference

Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules

21 January 2018

1 reference

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

Clusterin and chemoresistance

21 January 2018

1 reference

Clusterin expression in cholestasis, hepatocellular carcinoma and liver fibrosis

21 January 2018

1 reference

Management of metastatic castration-resistant prostate cancer: recent advances

21 January 2018

1 reference

Clinical significance of clusterin expression in pancreatic adenocarcinoma

21 January 2018

1 reference

Secreted CLU is associated with the initiation of triple-negative breast cancer.

21 January 2018

1 reference

Secreted clusterin in colon tumor cell models and its potential as diagnostic marker for colorectal cancer

21 January 2018

1 reference

Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting clusterin improves response to paclitaxel.

21 January 2018

1 reference

Clusterin as a predictor for chemoradiotherapy sensitivity and patient survival in esophageal squamous cell carcinoma

21 January 2018

1 reference

Evaluation of serum clusterin as a surveillance tool for human hepatocellular carcinoma with hepatitis B virus related cirrhosis.

21 January 2018

1 reference

Clinical significance of serum clusterin as a biomarker for evaluating diagnosis and metastasis potential of viral-related hepatocellular carcinoma

21 January 2018

1 reference

Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer

21 January 2018

1 reference

Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.

21 January 2018

1 reference

Antisense integrin alphaV and beta3 gene therapy suppresses subcutaneously implanted hepatocellular carcinomas

21 January 2018

1 reference

Downregulating hypoxia-inducible factor-2α improves the efficacy of doxorubicin in the treatment of hepatocellular carcinoma

21 January 2018

1 reference

Overexpression of von Hippel-Lindau protein synergizes with doxorubicin to suppress hepatocellular carcinoma in mice

21 January 2018

1 reference

Phospholipase A2-activating protein (PLAA) enhances cisplatin-induced apoptosis in HeLa cells

21 January 2018

1 reference

AKT as locus of cancer multidrug resistance and fragility

21 January 2018

1 reference

Clusterin, a novel modulator of TGF-beta signaling, is involved in Smad2/3 stability

21 January 2018

1 reference

CRM1 protein-mediated regulation of nuclear clusterin (nCLU), an ionizing radiation-stimulated, Bax-dependent pro-death factor

21 January 2018

1 reference

ATM-dependent IGF-1 induction regulates secretory clusterin expression after DNA damage and in genetic instability

21 January 2018

1 reference

Clusterin inhibits apoptosis by interacting with activated Bax

21 January 2018

1 reference

Clusterin induces the secretion of TNF-α and the chemotactic migration of macrophages

21 January 2018

1 reference

Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.

21 January 2018

1 reference

Clusterin induces matrix metalloproteinase-9 expression via ERK1/2 and PI3K/Akt/NF-κB pathways in monocytes/macrophages.

21 January 2018

1 reference

Glycogen synthase kinase-3 inhibitors augment TRAIL-induced apoptotic death in human hepatoma cells

21 January 2018

1 reference

Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells

21 January 2018

1 reference

Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy

21 January 2018

1 reference

Clusterin plays an important role in hepatocellular carcinoma metastasis

21 January 2018

1 reference

Overexpression of clusterin correlates with tumor progression, metastasis in gastric cancer: a study on tissue microarrays

21 January 2018

1 reference

Clusterin as a diagnostic and prognostic marker for transitional cell carcinoma of the bladder

21 January 2018

1 reference

12 December 2020

Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer

1 reference

12 December 2020

Overexpression of clusterin in human hepatocellular carcinoma

1 reference

12 December 2020

Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer

1 reference

12 December 2020

Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid

1 reference

12 December 2020

Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL

1 reference

12 December 2020

Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models

1 reference

12 December 2020

Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin

1 reference

12 December 2020

Clusterin immunoexpression and its clinical significance in patients with non-small cell lung cancer

1 reference

12 December 2020

Clusterin as a potential marker in distinguishing cervical neoplasia

1 reference

12 December 2020

Cellular and molecular pharmacology of oxaliplatin.

1 reference

12 December 2020

Multi-center phase II study of FLOX for advanced colorectal cancer patients in Japan: SWIFT 3 study

1 reference

12 December 2020

Identifiers

DOI

10.1111/CAS.12088

1 reference

release_uznaltnewjcbvheobzbocfsbr4

10 September 2017

0 references

1 reference